Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia

• Status: Completed
• Trial end date: 2017-12-21
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effects on emotions and neural activity of a one time dose of intranasal oxytocin vs. placebo in patients with FTD and healthy controls.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lawson Health Research Institute
• Collaborator: Canadian Institutes of Health Research (CIHR)
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

Patients:

• Ages 30-85

• meet consensus criteria for probable behavioural variant FTD (bvFTD)

Controls:

• Age and sex matched with patients

• Mini-Mental State Exam (MMSE) scores >27

Exclusion Criteria:

Patients:

• history of stroke

• intracranial haemorrhage or other medical or neurological disorder apart from FTD that could affect cognition

• diagnosis of bipolar disorder or schizophrenia not better accounted for by the diagnosis of FTD

• cognitive impairment that precludes comprehension of task instructions

• contraindication to MRI scanning

• severe language or memory deficits that preclude participation in the study visits and measures

• females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause).

• uncontrolled hypertension

• bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)

• current use of prostaglandins

Controls:

• history of stroke

• intracranial haemorrhage or other medical or neurological disorder

• diagnosis of bipolar disorder or schizophrenia

• cognitive impairment that precludes comprehension of task instructions

• contraindication to MRI scanning

• severe language or memory deficits that preclude participation in the study visits and measures

• females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause).

• uncontrolled hypertension

• bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)

• current use of prostaglandins